GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies

Abstract

Research has led to the development of tailored treatment options for different cancers in different patients. Despite some treatments being able to provide remarkable responses, nearly all current treatments encounter the same issue: resistance. Here, we discuss our experiences with how breast cancers resist therapies. The focus of our discussion revolves around the cancer stem cell subpopulation and their mechanisms for resistance.

Keywords

Drug resistance / breast cancer therapy / triple-negative breast cancer / cancer stem cells

References

[1] U.S. Breast cancer statistics. 2022. Available from: https://www.breastcancer.org/ [Last accessed on 7 Jun 2022]

[2] Bukowski K,Kontek R.Mechanisms of multidrug resistance in cancer chemotherapy.Int J Mol Sci2020;21:3233 PMCID:PMC7247559

[3] Wang X,Chen X.Drug resistance and combating drug resistance in cancer.Cancer Drug Resist2019;2:141-60 PMCID:PMC8315569

[4] Prat A,Adamo B.Clinical implications of the intrinsic molecular subtypes of breast cancer.The Breast2015;24:S26-35

[5] Dai X,Bai Z, et al.Breast cancer intrinsic subtype classification, clinical use and future trends.J Cancer Res Pract.2015;5:2929-43 PMCID:PMC4656721

[6] Burstein MD,Poage GM.Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.Clin Cancer Res2015;21:1688-98 PMCID:PMC4362882

[7] Lehmann BD,Chen X.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.J Clin Invest2011;121:2750-67

[8] Yin L,Bian XW.Triple-negative breast cancer molecular subtyping and treatment progress.Breast Cancer Res2020;22:61 PMCID:PMC7285581

[9] Loibl S.HER2-positive breast cancer.The Lancet2017;389:2415-29

[10] Arteaga CL,Osborne CK,Puglisi F.Treatment of HER2-positive breast cancer: current status and future perspectives.Nat Rev Clin Oncol2011;9:16-32

[11] Al-Mahmood S,Garbuzenko OB.Metastatic and triple-negative breast cancer: challenges and treatment options.Drug Deliv Transl Res2018;8:1483-507 PMCID:PMC6133085

[12] Yu KD,Zhan M.Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.Clin Cancer Res2013;19:2723-33 PMCID:PMC3655097

[13] McGranahan N.Clonal Heterogeneity and tumor evolution: past, present, and the future.Cell2017;168:613-28

[14] Jordan CT,Noble M.Cancer stem cells.N Engl J Med2006;355:1253-61

[15] Batlle E.Cancer stem cells revisited.Nat Med2017;23:1124-34

[16] Fillmore CM.Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.Breast Cancer Res2008;10:R25 PMCID:PMC2397524

[17] Malladi S,Jin X.Metastatic latency and immune evasion through autocrine inhibition of WNT.Cell2016;165:45-60 PMCID:PMC4808520

[18] Das S,Chatterjee R,Chatterji U.Enhancing chemosensitivity of breast cancer stem cells by downregulating SOX2 and ABCG2 using wedelolactone-encapsulated nanoparticles.Mol Cancer Ther2019;18:680-92

[19] Sun M,Zheng J.Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.Acta Biomater2015;28:171-82

[20] Takeda H,Suzuki S.Rho-Associated Protein Kinase (ROCK) inhibitors inhibit survivin expression and sensitize pancreatic cancer stem cells to gemcitabine.Anticancer Res2016;36:6311-8

[21] Li Y,Ajani JA.Drug resistance and cancer stem cells.Cell Commun Signal2021;19:19 PMCID:PMC7885480

[22] Park SY,Nam JS.Targeting cancer stem cells in triple-negative breast cancer.Cancers (Basel)2019;11:965 PMCID:PMC6678244

[23] Castillo V,Huidobro C,Castellon EA.Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer.Int J Oncol2014;45:985-94 PMCID:PMC4121425

[24] Dalerba P,Clarke MF.Cancer stem cells: models and concepts.Annu Rev Med2007;58:267-84

[25] Al-Hajj M,Benito-Hernandez A,Clarke MF.Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci USA2003;100:3983-8 PMCID:PMC153034

[26] Ginestier C,Charafe-Jauffret E.ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.Cell Stem Cell2007;1:555-67 PMCID:PMC2423808

[27] Colacino JA,Brooks MD.Heterogeneity of human breast stem and progenitor cells as revealed by transcriptional profiling.Stem Cell Reports2018;10:1596-609 PMCID:PMC5995162

[28] Battula VL,Evans KW.Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis.J Clin Invest2012;122:2066-78 PMCID:PMC3591166

[29] Wierzbicki A,Ciesielski M.Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells.J Immunol2008;181:6644-53 PMCID:PMC2730120

[30] Bolesta E,Wierzbicki A.DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.Cancer Res2005;65:3410-8

[31] Battula VL,Sun J.IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells.Oncotarget2017;8:36936-49 PMCID:PMC5514883

[32] Jaggupilli A,Nguyen K.Metabolic stress induces GD2⁺ cancer stem cell-like phenotype in triple-negative breast cancer.Br J Cancer2022;126:615-27

[33] Nguyen K,Yuan B.ST8SIA1 Regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway.Mol Cancer Ther2018;17:2689-701 PMCID:PMC6279518

[34] Ly S,El-Dana F.Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2⁺ breast cancer stem-like cells.J Immunother Cancer2021;9:e001197 PMCID:PMC7970220

[35] De Laurentiis M,Caputo R.Treatment of triple negative breast cancer (TNBC): current options and future perspectives.Cancer Treatment Reviews2010;36:S80-6

[36] Isakoff SJ.Triple-negative breast cancer: role of specific chemotherapy agents.Cancer J2010;16:53-61 PMCID:PMC2882502

[37] Seitz CM,Knopf P.GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.Oncoimmunology2020;9:1683345 PMCID:PMC6959445

[38] Ghosh A,James SE.Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.Nat Med2017;23:242-9 PMCID:PMC5528161

[39] Esser R,Stefes D.NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.J Cell Mol Med2012;16:569-81 PMCID:PMC3822932

[40] Markham A.Naxitamab: first approval.Drugs2021;81:291-6

[41] Cheung IY,Modak S.Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression.J Clin Oncol2021;39:215-26 PMCID:PMC8253584

[42] Sorkin LS,Baldwin WM 3rd.Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia.Pain2010;149:135-42 PMCID:PMC3755890

[43] Cavdarli S,Yamakawa N.Identification of 9-O-acetyl-N-acetylneuraminic acid (Neu5,9Ac₂) as main O-acetylated sialic acid species of GD2 in breast cancer cells.Glycoconj J2019;36:79-90

[44] Shao C,Andreeff M.Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer.Ann N Y Acad Sci2022;1508:35-53